Topic

IRA Negotiation

Medicare drug price negotiation, selected-drug lists, maximum fair price, and downstream lifecycle planning.

6 articles·Lives underPricing & Access Policy·Last updated 2026-05-21

Policy· May 21, 2026 · 8 min read

Medicare Part D redesign 2025-2026: what the IRA changed, what it costs, and what commercial teams should monitor

The Inflation Reduction Act eliminated the Part D donut hole, capped out-of-pocket drug spending at $2,100 for 2026, and restructured cost-sharing across three phases....

By Ran Chen#Medicare Part D #IRA Negotiation #Payer Policy

Pricing & Access· May 18, 2026 · 11 min read

Jardiance vs Farxiga: label, access, and payer coverage compared

Jardiance (empagliflozin) and Farxiga (dapagliflozin) are the two most prescribed SGLT2 inhibitors in the US, each with landmark cardiovascular and kidney outcome data....

By Ran Chen#SGLT2 Inhibitor #Payer Policy #Coverage Access

Pricing & Access· May 17, 2026 · 10 min read

Farxiga coverage guide: formulary, prior authorization, and what access teams should know

Farxiga (dapagliflozin) is an SGLT2 inhibitor approved for type 2 diabetes, heart failure, and chronic kidney disease. This guide maps FDA indications, dosing, formulary...

By Ran Chen#SGLT2 Inhibitor #Formulary #Prior Authorization

Pricing & Access· May 17, 2026 · 9 min read

Jardiance coverage guide: formulary, prior authorization, and what access teams should know

Jardiance (empagliflozin) is an SGLT2 inhibitor approved for type 2 diabetes, heart failure, and chronic kidney disease. This guide maps FDA indications, dosing,...

By Ran Chen#SGLT2 Inhibitor #Formulary #Prior Authorization

Pricing & Access· May 16, 2026 · 11 min read

Eliquis vs Xarelto: label, access, and payer coverage compared

Eliquis (apixaban) and Xarelto (rivaroxaban) are the two most prescribed direct oral anticoagulants in the U.S. Both were selected for the first round of IRA Medicare...

By Ran Chen#DOAC #Anticoagulant #Prior Authorization

Pricing & Access· May 11, 2026 · 4 min read

IRA negotiation after the headline price: what access teams should watch

Maximum fair price is only the first-order signal. The second-order work is lifecycle planning, formulary response, therapeutic alternatives, and patient-out-of-pocket...

By Ran Chen#IRA Negotiation #Payer Policy #Coverage Access